Peptide Schedule
Nesiritide (Natrecor)32 residuesSPKMVQGSGCFGRKMDRISSSSGLGCKVLRRHEach bubble = one amino acid. Size = residue mass. Color = chemical class.Nesiritide (Natrecor) Dosage Calculator
Nesiritide (brand name Natrecor) is a recombinant human B-type natriuretic peptide (rhBNP) approved by the FDA in 2001 for the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
1mcg · Single dose
Summary: Add 0mL BAC water to your 1.5mg vial. Draw to < 0.1 units on a U-100 syringe for a 1mcg dose. This vial will last 0 doses.
Cycle Planner
Nesiritide (Natrecor) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = 18 minutesDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Nesiritide (Natrecor) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mcg | Single dose |
| Moderate | 2mcg | Single dose |
| Aggressive | 2mcg | Single dose |
Note: Nesiritide (Natrecor) is a recombinant form of human B-type natriuretic peptide (BNP) identical to the endogenous 32-amino-acid peptide produced by the ventricular myocardium in response to volume overload and increased wall stress. It is FDA-approved exclusively for IV use in hospitalized patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity. The recommended regimen is a 2 mcg/kg IV bolus over 60 seconds followed by a continuous infusion at 0.01 mcg/kg/min. Nesiritide should not be used as a substitute for diuretics and must be administered under hemodynamic monitoring. The ASCEND-HF trial (2011) showed nesiritide did not reduce mortality or rehospitalization versus placebo but did modestly improve dyspnea. It is not intended for outpatient, intermittent, or scheduled repetitive use.
About Nesiritide (Natrecor)
Nesiritide (brand name Natrecor) is a recombinant human B-type natriuretic peptide (rhBNP) approved by the FDA in 2001 for the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. The peptide has an identical amino acid sequence to the endogenous BNP produced by ventricular cardiomyocytes in response to myocardial wall stress and volume overload. Nesiritide binds to natriuretic peptide receptor-A (NPR-A) on vascular smooth muscle and endothelial cells, activating particulate guanylyl cyclase and increasing intracellular cyclic guanosine monophosphate (cGMP). This cGMP-mediated signaling cascade produces balanced arterial and venous vasodilation, reduces cardiac preload and afterload, and promotes natriuresis and diuresis. The net hemodynamic effect is a rapid reduction in pulmonary capillary wedge pressure (PCWP), right atrial pressure, and systemic vascular resistance, along with an increase in cardiac output without direct inotropic stimulation. The landmark VMAC trial (2002) demonstrated that nesiritide significantly reduced PCWP compared to IV nitroglycerin and placebo, and improved patient-reported dyspnea scores. The subsequent large-scale ASCEND-HF trial (2011, n=7,141) showed that nesiritide modestly improved dyspnea but did not reduce 30-day mortality or heart failure rehospitalization compared to placebo. Nesiritide is administered as a weight-based IV bolus of 2 mcg/kg followed by a continuous infusion at 0.01 mcg/kg/min for up to 48 hours in hospitalized settings. It is not recommended for outpatient or intermittent scheduled use. Common adverse effects include hypotension, headache, and potential worsening of renal function in susceptible patients. Despite its initial promise, clinical use has declined significantly following the ASCEND-HF results, though it remains FDA-approved and available for acute hemodynamic stabilization in selected patients.